1. Home
  2. UTL vs ABUS Comparison

UTL vs ABUS Comparison

Compare UTL & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UNITIL Corporation

UTL

UNITIL Corporation

HOLD

Current Price

$51.11

Market Cap

906.9M

Sector

Utilities

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.44

Market Cap

848.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UTL
ABUS
Founded
1984
2005
Country
United States
United States
Employees
N/A
19
Industry
Power Generation
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
906.9M
848.8M
IPO Year
1995
2008

Fundamental Metrics

Financial Performance
Metric
UTL
ABUS
Price
$51.11
$4.44
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$56.50
$5.00
AVG Volume (30 Days)
83.8K
1.6M
Earning Date
05-04-2026
05-14-2026
Dividend Yield
3.65%
N/A
EPS Growth
1.37
55.26
EPS
1.85
0.87
Revenue
$536,000,000.00
$14,083,000.00
Revenue This Year
$5.43
N/A
Revenue Next Year
$4.22
$239.71
P/E Ratio
$27.60
$4.80
Revenue Growth
8.33
128.21
52 Week Low
$45.11
$3.04
52 Week High
$55.12
$5.10

Technical Indicators

Market Signals
Indicator
UTL
ABUS
Relative Strength Index (RSI) 47.33 55.32
Support Level $51.05 $4.17
Resistance Level $53.65 $4.60
Average True Range (ATR) 1.19 0.16
MACD 0.03 0.00
Stochastic Oscillator 50.12 81.25

Price Performance

Historical Comparison
UTL
ABUS

About UTL UNITIL Corporation

Unitil Corp through its subsidiaries engages in the distribution of electricity and natural gas in its service territories in the states of New Hampshire, Massachusetts and Maine. Its natural gas operations include gas distribution utility operations and interstate gas transmission pipeline operations. It also engages in interstate natural gas transmission pipeline company, operating approximately 85 miles of underground gas transmission pipeline located in Maine and New Hampshire. The company's segments include Electric and Gas.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: